Study guide

9.3 Local Anaesthetic Pharmacology, Toxicity (LAST), and Lipid Emulsion Therapy

EDAIC Part I European Diploma in Anaesthesiology and Intensive Care

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: The EDAIC Part I Examination

1.1 EDAIC Part I Exam Format, Scoring and Multiple True/False Strategy

2 Chapter 2: Anatomy for Anaesthesia and Intensive Care

2.1 Functional Anatomy of the Upper Airway, Larynx, and Tracheobronchial Tree 2.2 Neuraxial Anatomy: Spine, Spinal Cord, Meninges, and Spaces 2.3 Vascular Anatomy for Central and Peripheral Cannulation 2.4 Peripheral Nerve Plexuses and Autonomic Nervous System Pathways 2.5 Thoracic Anatomy: Chest Wall, Intercostal Spaces, Pleura, Mediastinum and Heart

3 Chapter 3: Respiratory and Cardiovascular Physiology

3.1 Respiratory Mechanics, Lung Volumes, and Work of Breathing 3.2 Ventilation-Perfusion Relationships, Shunt, and Gas Exchange 3.3 Control of Breathing, Hypoxia, Altitude and Hyperbaric Physiology 3.4 Cardiac Cycle, Electrophysiology, and Ventricular Function 3.5 Vascular Resistance, Microcirculation, and Systemic Hemodynamics

4 Chapter 4: Neurophysiology, Renal, Hepatic and Acid-Base Physiology

4.1 Cerebral Blood Flow, Intracranial Pressure, and CSF Dynamics 4.2 Renal Physiology, Glomerular Filtration, and Tubular Transport 4.3 Hepatic Blood Flow, Metabolism, and Clearance 4.4 Acid-Base Regulation, Buffering Systems, and Stewart Approach

5 Chapter 5: Endocrine and Haematological Physiology

5.1 Endocrine Physiology and the Neuroendocrine Stress Response 5.2 Haemostasis Physiology, Coagulation Testing and Inherited Bleeding Disorders

6 Chapter 6: Special Patient Physiology: Maternal, Paediatric and Geriatric

6.1 Maternal Physiological Adaptations to Pregnancy and Uteroplacental Flow 6.2 Neonatal and Paediatric Physiological Differences 6.3 Physiological Changes of Ageing and Thermoregulation

7 Chapter 7: General Pharmacological Principles and Inhalational Anaesthetics

7.1 Pharmacokinetic Principles, Compartmental Models, and Clearance 7.2 Pharmacodynamic Mechanisms, Receptor Theory, and Drug Interactions 7.3 Physical Properties, Uptake, and Distribution of Volatile Anaesthetics 7.4 Minimum Alveolar Concentration (MAC), Organ Effects, and Toxicity

8 Chapter 8: Intravenous Agents, Neuromuscular Blockade and Analgesics

8.1 Intravenous Induction Agents: Propofol, Etomidate, Ketamine, and Barbiturates 8.2 Neuromuscular Blocking Agents: Depolarizing and Non-Depolarizing Drugs 8.3 Neuromuscular Monitoring and Reversal: Anticholinesterases and Sugammadex 8.4 Opioid Pharmacology, Receptors, and Non-Opioid Analgesic Agents

9 Chapter 9: Cardiovascular Drugs, Autonomic Pharmacology and Local Anaesthetics

9.1 Inotropes, Vasopressors, and Inodilators in Perioperative Care 9.2 Antiarrhythmic, Antihypertensive, and Beta-Adrenergic Antagonist Drugs 9.3 Local Anaesthetic Pharmacology, Toxicity (LAST), and Lipid Emulsion Therapy

10 Chapter 10: Haematological and Internal Medicine Pharmacology

10.1 Anticoagulant, Antiplatelet and Haemostatic Drugs and Their Reversal 10.2 Internal Medicine Drugs: Endocrine, Respiratory, Psychiatric and Antiepileptic Agents and Their Anaesthetic Interactions

11 Chapter 11: Physics, Clinical Measurement and Medical Equipment

11.1 Physical Gas Laws, Fluid Dynamics, and Resistance Principles 11.2 Anaesthetic Machines, Gas Supply Pipelines, Cylinders, and Safety Mechanisms 11.3 Breathing Systems, Vaporizer Mechanics, and Scavenging Systems 11.4 Invasive and Non-Invasive Hemodynamic and Respiratory Monitoring

12 Chapter 12: Electrical Safety, Temperature, Humidity and Gas Analysis

12.1 Electricity, Electrical Safety, Diathermy, Defibrillation, Implanted Devices and Fire 12.2 Temperature Measurement, Humidity, Gas Analysis and SI Units

13 Chapter 13: Biostatistics, Clinical Trials and Evidence Appraisal

13.1 Descriptive Statistics, Distributions, and Parametric vs Non-Parametric Tests 13.2 Hypothesis Testing, Power, Type I/II Errors, and Confidence Intervals 13.3 Clinical Study Designs, Bias, and Diagnostic Test Performance (Sensitivity, Specificity, ROC)

14 Chapter 14: General Anaesthesia, Preoperative Evaluation and Airway Management

14.1 Preoperative Risk Assessment, Cardiovascular Risk Indices, and Fasting Guidelines 14.2 The Difficult Airway: Assessment, Algorithms, and Rescue Oxygenation 14.3 Intraoperative Fluid Therapy, Goal-Directed Hemodynamics, and Blood Conservation 14.4 Post-Anaesthesia Care Unit (PACU) Management, Emergence, and Postoperative Nausea/Vomiting

15 Chapter 15: Coexisting Disease and Preoperative Investigations

15.1 Interpreting Investigations: ECG, Chest Radiograph, Lung Function and Blood Tests 15.2 Coexisting Disease I: Asthma, COPD, Obstructive Sleep Apnoea, Obesity, Liver and Renal Disease 15.3 Endocrine Disease and Emergencies: Diabetes, DKA and HHS, Thyroid, Adrenal, Phaeochromocytoma and Carcinoid 15.4 Coexisting Disease II: Neuromuscular and Neurological Disease

16 Chapter 16: Subspecialty Anaesthesia: Cardiothoracic, Vascular and Neuroanaesthesia

16.1 Anaesthesia for Cardiac Surgery and Cardiopulmonary Bypass Management 16.2 Thoracic Anaesthesia, One-Lung Ventilation, and Major Vascular Surgery 16.3 Neuroanaesthesia: Craniotomy, Sitting Position, and Traumatic Brain Injury

17 Chapter 17: Obstetric, Paediatric and Ambulatory Anaesthesia

17.1 Obstetric Analgesia and Anaesthesia: Labour, Caesarean Delivery, and High-Risk Conditions 17.2 Paediatric Anaesthesia: Induction, Airway Management, and Emergencies 17.3 Ambulatory Day-Surgery Selection, Premedication, and Elderly Patient Anaesthesia

18 Chapter 18: Anaesthetic Complications and Specialty Settings

18.1 Anaesthetic Complications: Accidental Awareness, Aspiration, Positioning Injuries, Visual Loss and Dental Damage 18.2 Anaesthesia for ENT and Laser Airway Surgery, Ophthalmic Surgery, and Laparoscopic and Robotic Surgery

19 Chapter 19: Regional Anaesthesia and Acute/Chronic Pain Management

19.1 Neuraxial Techniques: Spinal, Epidural, and Caudal Anaesthesia 19.2 Upper and Lower Limb Peripheral Nerve and Fascial Plane Blocks 19.3 Multimodal Acute Postoperative Pain Management and ERAS Pathways 19.4 Chronic and Neuropathic Pain Syndromes and Interventional Management 19.5 Palliative Symptom Control, Psychological Aspects of Pain and Multidisciplinary Pain Management

20 Chapter 20: Intensive Care Medicine: Ventilation, Shock and Organ Support

20.1 Acute Respiratory Distress Syndrome (ARDS) and Mechanical Ventilation Strategies 20.2 Sepsis-3 Definitions, Septic Shock, and Hemodynamic Resuscitation 20.3 Acute Kidney Injury, Indications for Dialysis, and Continuous Renal Replacement Therapy 20.4 ICU Sedation, Delirium, Weaning, and Brain Death Determination

21 Chapter 21: Intensive Care Medicine: Admission, Nutrition, Infection and Electrolytes

21.1 ICU Admission, Severity Scoring, Nutrition and Routine Prophylaxis 21.2 Antimicrobial Therapy, Stewardship and ICU-Acquired Infections 21.3 Electrolyte Disorders: Sodium, Potassium, Calcium, Magnesium and Phosphate

22 Chapter 22: Intensive Care and Emergency Medicine: Neurocritical Care, Poisoning and Cardiorespiratory Emergencies

22.1 Neurocritical Care: Subarachnoid Haemorrhage, Stroke, Status Epilepticus and Acute Neuromuscular Failure 22.2 Acute Poisoning: Toxidromes, Decontamination and Specific Antidotes 22.3 Acute Cardiorespiratory Emergencies: Pulmonary Embolism, Acute Severe Asthma and COPD, Non-Invasive Support and Acute Heart Failure

23 Chapter 23: Resuscitation, Perioperative Emergencies and Professional Ethics

23.1 Advanced Life Support (ALS) Guidelines and Perioperative Cardiac Arrest 23.2 Perioperative Crises: Malignant Hyperthermia and Severe Anaphylaxis 23.3 Major Trauma, Hemorrhagic Shock, and Massive Transfusion Protocols 23.4 Professional Ethics, Informed Consent, Patient Safety, and Helsinki Declaration

24 Chapter 24: Newborn, Paediatric and Obstetric Emergencies

24.1 Newborn Life Support and Paediatric Life Support 24.2 Obstetric Emergencies: Maternal Collapse, Amniotic Fluid Embolism, Uterine Inversion and Resuscitative Hysterotomy

25 Chapter 25: Burns, Environmental Emergencies and Patient Transport

25.1 Burns, Inhalation Injury, Drowning, Hypothermia, Heat Illness and Decompression Illness 25.2 Prehospital Care and Intra- and Inter-Hospital Transport of the Critically Ill

9.3 Local Anaesthetic Pharmacology, Toxicity (LAST), and Lipid Emulsion Therapy

Key Takeaways Explain This Topic AI

Local anaesthetics consist of a lipophilic aromatic ring, an intermediate chain (ester or amide, identified by the classic rule: 'two I's = amide', 'one I = ester'), and a hydrophilic tertiary amine; esters are rapidly hydrolyzed in plasma by pseudocholinesterase yielding allergenic para-aminobenzoic acid (PABA), whereas amides undergo hepatic microsomal cytochrome P450 metabolism.

Local anaesthetics block voltage-gated sodium channels ( N a V 1.1 − 1.9 Na_V1.1-1.9 N a V ​ 1.1 − 1.9 ) from the intracellular axoplasmic side; the uncharged free base ( B B B ) must permeate the lipid axonal membrane before intracellular protonation into the charged cation ( B H + BH^+ B H + ), which binds the inner channel receptor pore; according to the modulated receptor hypothesis, local anaesthetics exhibit state-dependent block, binding preferentially to open and inactivated channel conformations.

Clinical onset is governed inversely by p K a pK_a p K a ​ (a p K a pK_a p K a ​ closer to physiological pH 7.4 yields a higher uncharged base fraction capable of rapid membrane penetration), potency is determined by lipid solubility (octanol:water partition coefficient), and duration of action correlates with plasma and tissue protein binding (primarily to α 1 \alpha_1 α 1 ​ -acid glycoprotein).

Bupivacaine exhibits disproportionate cardiotoxicity because it binds avidly to cardiac sodium channels ( N a V 1.5 Na_V1.5 N a V ​ 1.5 ) during systole and dissociates very slowly during diastole ('fast in, slow out' kinetics), yielding a low cardiovascular-to-CNS toxicity ratio ( CC/CNS ≈ 2.0 \text{CC/CNS} \approx 2.0 CC/CNS ≈ 2.0 ) compared to lidocaine ( CC/CNS ≈ 7.0 \text{CC/CNS} \approx 7.0 CC/CNS ≈ 7.0 ); pure S ( − ) S(-) S ( − ) -enantiomers (levobupivacaine and ropivacaine) offer significantly greater margins of cardiac safety.

The definitive management of Local Anaesthetic Systemic Toxicity (LAST) requires immediate cessation of injection, airway management with 100% O 2 \text{O}_2 O 2 ​ and avoidance of hypercapnia/acidosis, seizure suppression with benzodiazepines, avoidance of standard ACLS epinephrine doses (use reduced boluses < 1 mcg/kg <1\text{ mcg/kg} < 1 mcg/kg ), avoidance of vasopressin and calcium channel blockers, and rapid administration of 20% lipid emulsion ( 1.5 mL/kg 1.5\text{ mL/kg} 1.5 mL/kg bolus over 1 minute followed by 0.25 mL/kg/min 0.25\text{ mL/kg/min} 0.25 mL/kg/min infusion, up to a maximum of 12 mL/kg 12\text{ mL/kg} 12 mL/kg ).

Last updated: October 2026

9.3 Local Anaesthetic Pharmacology, Toxicity (LAST), and Lipid Emulsion Therapy

Local anaesthetics reversibly interrupt neural conduction along peripheral and central axonal pathways by inhibiting voltage-gated sodium channels. Their therapeutic efficacy, duration of sensory and motor blockade, and potential for catastrophic systemic toxicity are directly dictated by their molecular architecture, physicochemical properties, and intracellular binding dynamics.

1. Chemical Architecture and Classification

All clinically utilized local anaesthetics share a common tripartite molecular framework: [ LIPOPHILIC AROMATIC RING ] ------ [ INTERMEDIATE CHAIN ] ------ [ HYDROPHILIC AMINE ]

  • (Benzene Ring) (Ester or Amide) (Tertiary Amine)
  • | | |
  • Confers Lipid Determines Pathway Accepts Proton;
  • Solubility & Potency of Elimination & Allergy Exists as Base (B) or Cation (BH+)

Lipophilic Aromatic Group: Typically a substituted benzene ring that facilitates diffusion across hydrophobic lipoprotein neural membranes.

Intermediate Chain: A hydrocarbon chain linking the aromatic head to the amine tail via either an ester ( − C O O − -COO- − COO − ) or an amide ( − N H C O − -NHCO- − N H CO − ) bond.

Hydrophilic Amine Group: Usually a tertiary or secondary amine that acts as a weak base, accepting a hydrogen ion ( H + H^+ H + ) to become a charged cation.

The "I" Mnemonic and Metabolic Pathways

Amides ("Two I's"): L i doca i ne, bup i vaca i ne, rop i vaca i ne, pr i loca i ne, levobup i vaca i ne, and art i ca i ne (articaine contains both an amide linkage and an ancillary ester group on its thiophene ring).

Metabolism: Amides undergo extensive hepatic microsomal degradation by cytochrome P450 enzymes (predominantly CYP1A2 and CYP3A4), involving dealkylation and hydroxylation. Elimination half-lives are relatively long (lidocaine 1.5 − 2 hours 1.5 - 2\text{ hours} 1.5 − 2 hours , bupivacaine 3.5 hours 3.5\text{ hours} 3.5 hours ). Clearance is directly dependent on hepatic blood flow and intrinsic enzyme function. True IgE-mediated allergic reactions to amides are vanishingly rare ( < 1 % <1\% < 1% of all adverse events); when hypersensitivity occurs, it is almost universally triggered by the preservative methylparaben (structurally similar to PABA) or sodium metabisulfite added to multi-dose vials.

Esters ("One I"): Procaine, tetracaine, chloroprocaine, cocaine, and benzocaine (the only "i" is in the shared "-caine" suffix).

Metabolism: Esters are rapidly hydrolyzed in the bloodstream and tissues by circulating plasma butyrylcholinesterase (pseudocholinesterase) . Elimination half-lives are exceptionally short (chloroprocaine < 1 minute <1\text{ minute} < 1 minute ). Ester hydrolysis generates para-aminobenzoic acid (PABA) and its derivatives, which act as potent haptens capable of sensitizing lymphocytes and triggering true IgE-mediated anaphylaxis. Patients with congenital pseudocholinesterase deficiency (atypical enzyme) exhibit prolonged clearance and heightened toxicity risks from ester local anaesthetics.

2. Mechanism of Action and the Modulated Receptor Hypothesis

Local anaesthetics interrupt the generation and propagation of action potentials along excitable neural membranes by binding to the pore-forming alpha-subunit of voltage-gated sodium channels ( N a V 1.1 Na_V1.1 N a V ​ 1.1 to N a V 1.9 Na_V1.9 N a V ​ 1.9 ) . [ AXONAL MEMBRANE PERMEATION ]

  • EXTRACELLULAR SPACE (pH 7.4) INTRACELLULAR AXOPLASM (pH 7.2)
  • ============================ ===============================
  • BH+ (85%) BH+ (Active Cation)
  • ^ ^
  • | |
  • (H+) + B (15%) ----------> [ DIFFUSION ] ------> B + (H+)
  • [Uncharged] Through Lipid [Uncharged]
  • Bilayer
  • |
  • v
  • [ Binds to S6 Domain IV ]
  • Inside NaV Channel Pore
  • From the Cytoplasmic Face
  • |
  • v
  • Blocks Na+ Influx -> Apnea of Conduction
  • The Dual-Form Equilibrium

Local anaesthetics exist in an aqueous equilibrium between an uncharged, non-ionized lipophilic free base ( B \text{B} B ) and a positively charged, ionized hydrophilic cation ( BH + \text{BH}^+ BH + ): B + H + ⇌ BH + \text{B} + \text{H}^+ \xrightleftharpoons{} \text{BH}^+ B + H + ​ BH +

Membrane Penetration: The lipid bilayer of the perineurium and axonal membrane represents an impermeable barrier to charged ions. Only the uncharged lipophilic base ( B \text{B} B ) can cross the axonal membrane into the cytoplasm.

Channel Blockade: Once inside the axoplasm (pH ~7.2), the molecule re-equilibrates. The charged cation ( BH + \text{BH}^+ BH + ) binds with high affinity to a specific receptor binding site located within the inner vestibule of the sodium channel pore (specifically residues on the S6 transmembrane segment of domain IV ). Positively charged BH + \text{BH}^+ BH + sterically occludes the pore and electrostatically repels incoming sodium ions, preventing the regenerative depolarizing Phase 0 inward sodium current.

The Modulated Receptor Hypothesis (Hille)

Voltage-gated sodium channels cycle through three distinct functional conformations:

Resting (Closed): The activation gate is closed; the inactivation gate is open.

Open (Activated): Membrane depolarization triggers rapid opening of the activation gate; N a + Na^+ N a + ions rush into the cell.

Inactivated (Refractory): Within 1 millisecond, the intracellular inactivation loop (the IFM motif: isoleucine-phenylalanine-methionine) swings into the inner pore, plugging the channel.

Local anaesthetic molecules possess dramatically higher binding affinity for the open and inactivated states than for the resting state. As a result, repetitive, high-frequency neural firing drives channels into the high-affinity open/inactivated configurations, accelerating and intensifying the block—a phenomenon designated use-dependent (or frequency-dependent) blockade . Nerves that fire at high frequencies (such as sensory pain C-fibers and A δ A\delta A δ -fibers) are blocked far more rapidly than infrequently firing motor fibers.

Differential Nerve Block Sensitivity

Susceptibility of peripheral nerve fibers to local anaesthetic blockade depends on fiber diameter, myelination, and conduction velocity:

B B B -Fibers: Small diameter ( < 3 μ m <3\text{ }\mu\text{m} < 3 μ m ), lightly myelinated preganglionic autonomic fibers; the most sensitive to blockade. Sympathetic blockade typically extends 2 to 4 dermatomes higher than sensory blockade during neuraxial anaesthesia.

A δ A\delta A δ and C C C Fibers: Small diameter, transmitting dull/sharp pain and temperature; blocked early.

A β A\beta A β and A γ A\gamma A γ Fibers: Intermediate diameter, transmitting touch, pressure, and muscle spindle afferents; intermediate sensitivity.

A α A\alpha A α Fibers: Large diameter ( 12 − 20 μ m 12 - 20\text{ }\mu\text{m} 12 − 20 μ m ), heavily myelinated somatic motor and proprioceptive fibers; the most resistant to blockade (requiring highest drug concentrations).

3. Physicochemical Determinants of Clinical Performance

Property Primary Physicochemical Determinant Mechanism / Clinical Rule

Potency Lipid Solubility (Octanol:water partition coefficient) More lipophilic drugs partition readily into the neural membrane; fewer molecules are required to extinguish conduction. E.g., Bupivacaine (partition coefficient ~1000) is 4 times more potent than Lidocaine (~110).

Onset of Action Dissociation Constant ( p K a pK_a p K a ​ ) Governed by the Henderson-Hasselbalch equation: pH − p K a = log ⁡ 10 ( [ B ] / [ BH + ] ) \text{pH} - pK_a = \log_{10}([\text{B}]/[\text{BH}^+]) pH − p K a ​ = lo g 10 ​ ([ B ] / [ BH + ]) . Drugs with p K a pK_a p K a ​ closer to physiological pH (7.4) have a larger fraction of uncharged base ( B B B ) available to cross membranes, accelerating onset.

Duration of Action Protein Binding ( α 1 \alpha_1 α 1 ​ -Acid Glycoprotein and Albumin) Local anaesthetics bind to plasma and tissue proteins. Drugs with high protein binding remain anchored to the sodium channel receptor site longer, prolonging clinical block duration.

Vasoactive Properties Intrinsic vascular smooth muscle effect Almost all local anaesthetics cause vasodilation at clinical concentrations. Exceptions: Cocaine (vasoconstrictor via Uptake-1 blockade) and Ropivacaine / Levobupivacaine (intrinsic vasoconstriction at low doses).

Physicochemical Profiles of Common Local Anaesthetics

Agent Class p K a pK_a p K a ​ % Base at pH 7.4 Protein Binding (%) Relative Potency Clinical Onset Clinical Duration

Chloroprocaine Ester 8.7 ~5% ~7% 1 Very Fast (high conc) Short ( 30 − 60 min 30 - 60\text{ min} 30 − 60 min )

Lidocaine Amide 7.9 ~25% 64% 2 Fast ( 2 − 5 min 2 - 5\text{ min} 2 − 5 min ) Intermediate ( 90 − 150 min 90 - 150\text{ min} 90 − 150 min )

Mepivacaine Amide 7.6 ~39% 77% 2 Fast ( 3 − 5 min 3 - 5\text{ min} 3 − 5 min ) Intermediate ( 120 − 180 min 120 - 180\text{ min} 120 − 180 min )

Prilocaine Amide 7.9 ~25% 55% 2 Fast ( 2 − 4 min 2 - 4\text{ min} 2 − 4 min ) Intermediate ( 100 − 160 min 100 - 160\text{ min} 100 − 160 min )

Bupivacaine Amide 8.1 ~15% 95% 8 Slow ( 10 − 20 min 10 - 20\text{ min} 10 − 20 min ) Long ( 240 − 480 min 240 - 480\text{ min} 240 − 480 min )

Ropivacaine Amide 8.1 ~15% 94% 6 Moderate ( 8 − 15 min 8 - 15\text{ min} 8 − 15 min ) Long ( 240 − 420 min 240 - 420\text{ min} 240 − 420 min )

Levobupivacaine Amide 8.1 ~15% 95% 8 Moderate/Slow Long ( 240 − 480 min 240 - 480\text{ min} 240 − 480 min )

Tetracaine Ester 8.4 ~9% 76% 8 Slow ( 10 − 20 min 10 - 20\text{ min} 10 − 20 min ) Long ( 180 − 300 min 180 - 300\text{ min} 180 − 300 min )

The Chloroprocaine Paradox

Under strict Henderson-Hasselbalch kinetics, chloroprocaine ( p K a = 8.7 pK_a = 8.7 p K a ​ = 8.7 ) has only ~5% of its molecules in the uncharged base form at pH 7.4, which theoretically should produce a sluggish onset. However, in clinical practice, chloroprocaine has the fastest onset of all local anaesthetics . Because chloroprocaine is rapidly degraded by pseudocholinesterase in plasma, its systemic toxicity profile is exceptionally benign, allowing it to be safely formulated and administered at a massive concentration ( 2% to 3% = 20 to 30 mg/mL ; compared to bupivacaine at 0.25% to 0.5% = 2.5 to 5 mg/mL). The sheer concentration gradient drives a vast absolute number of uncharged base molecules across the axonal membrane per unit time, overwhelming the low percentage fraction.

The Acidotic Tissue Trap

In infected or inflamed tissue, the extracellular microenvironment is acidic (pH drops to 5.5 − 6.2 5.5 - 6.2 5.5 − 6.2 ). Under these conditions, the Henderson-Hasselbalch equilibrium shifts massively to the left: pH − p K a = log ⁡ 10 ( [ B ] [ BH + ] ) \text{pH} - pK_a = \log_{10}\left(\frac{[\text{B}]}{[\text{BH}^+]}\right) pH − p K a ​ = lo g 10 ​ ( [ BH + ] [ B ] ​ ) Virtually 99.9% of the local anaesthetic is trapped in the charged, impermeable cationic form ( BH + \text{BH}^+ BH + ). Because almost no uncharged base ( B \text{B} B ) exists to permeate the nerve sheath, local anaesthesia fails completely when injected directly into infected or phlegmonous tissues.

  • 4. Local Anaesthetic Additives and Special Toxicities
  • Additives

Epinephrine ( 1 : 200,000 1:200{,}000 1 : 200 , 000 or 5 mcg/mL 5\text{ mcg/mL} 5 mcg/mL ): Induces local α 1 \alpha_1 α 1 ​ -mediated arteriolar vasoconstriction, which slows systemic vascular absorption, decreases peak arterial plasma drug concentration ( C max ⁡ C_{\max} C m a x ​ ), and prolongs the duration of neural blockade by up to 50% for intermediate-acting agents (lidocaine). In addition, it serves as an immediate marker of accidental intravascular injection (producing an instantaneous heart rate increase > 10 bpm >10\text{ bpm} > 10 bpm or systolic blood pressure rise > 15 mmHg >15\text{ mmHg} > 15 mmHg ). Epinephrine is relatively contraindicated in regions with compromised terminal end-arterial perfusion (digits, penis, tip of nose).

Sodium Bicarbonate ( 8.4 % 8.4\% 8.4% ): Adding 1 mL of 8.4 % 8.4\% 8.4% NaHCO 3 \text{NaHCO}_3 NaHCO 3 ​ to 10 mL of 1% or 2% lidocaine raises the pH of the commercial solution (which is acidic, especially epinephrine-containing preparations, to prolong shelf-life). Alkalinization substantially increases the percentage of uncharged base, dramatically accelerating the onset of neural blockade and reducing the stinging sensation upon subcutaneous infiltration.

Perineural Adjuvants: Dexamethasone ( 2 − 4 mg 2 - 4\text{ mg} 2 − 4 mg preservative-free), clonidine ( 0.5 − 1.0 mcg/kg 0.5 - 1.0\text{ mcg/kg} 0.5 − 1.0 mcg/kg ), and dexmedetomidine ( 0.5 − 1.0 mcg/kg 0.5 - 1.0\text{ mcg/kg} 0.5 − 1.0 mcg/kg ) prolong sensory block duration by suppressing nociceptive C-fiber discharge and mediating local vasoconstriction.

Prilocaine and Methemoglobinemia

Prilocaine undergoes hepatic metabolism by cytochrome P450 enzymes to produce the aromatic metabolite o o o -toluidine (ortho-toluidine) . o o o -Toluidine is an oxidant that oxidizes the ferrous iron ( F e 2 + Fe^{2+} F e 2 + ) of normal hemoglobin to the ferric iron ( F e 3 + Fe^{3+} F e 3 + ) state, forming methemoglobin ( M e t H b MetHb M e t H b ) : Hemoglobin-Fe 2 + → o -Toluidine Methemoglobin-Fe 3 + \text{Hemoglobin-Fe}^{2+} \xrightarrow{o\text{-Toluidine}} \text{Methemoglobin-Fe}^{3+} Hemoglobin-Fe 2 + o -Toluidine ​ Methemoglobin-Fe 3 +

Consequences: Ferric iron ( F e 3 + Fe^{3+} F e 3 + ) cannot bind oxygen. Furthermore, its presence distorts the remaining ferrous heme groups within the hemoglobin tetramer, shifting the oxygen-hemoglobin dissociation curve sharply to the left and impeding tissue oxygen offloading.

Clinical Presentation: Asymptomatic slate-grey cyanosis refractory to supplemental oxygen, chocolate-brown arterial blood, and a pulse oximetry reading that plateaus stubbornly at ~85% (because methemoglobin exhibits equal light absorbance at both 660 nm and 940 nm wavelengths).

Definitive Treatment: Administer Methylene Blue ( 1 − 2 mg/kg 1 - 2\text{ mg/kg} 1 − 2 mg/kg IV over 5 minutes) . Methylene blue acts as an electron acceptor/donor for the NADPH-methemoglobin reductase pathway, accelerating the enzymatic reduction of M e t H b MetHb M e t H b back to functional hemoglobin. It is strictly contraindicated in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency (in whom methylene blue cannot be reduced to leukomethylene blue and may precipitate massive hemolytic anemia).

5. Local Anaesthetic Systemic Toxicity (LAST)

LAST is a potentially fatal adverse event resulting from excessive systemic plasma concentrations of local anaesthetic, triggered either by accidental direct intravascular injection or by rapid systemic absorption from vascular anatomical sites . [ SYSTEMIC ABSORPTION HIERARCHY: HIGHEST TO LOWEST ]

  • Intravenous > Tracheal > Intercostal > Caudal > Paracervical > Epidural >
  • Brachial Plexus > Femoral / Sciatic > Subcutaneous Infiltration
  • (Mnemonic: 'In Time I Can Pull Every Boy Fooled Soon') [ CELLULAR PATHOPHYSIOLOGY OF LAST ]
  • |
  • +------------------------------+------------------------------+
  • | |
  • [ CENTRAL NERVOUS SYSTEM ] [ CARDIOVASCULAR SYSTEM ]
  • Local anaesthetics cross blood-brain barrier Direct Myocardial Infiltration
  • | |
  • Selectively Depress Inhibitory Cortical Neurons 1. Blocks Cardiac Sodium Channels (NaV1.5)
  • (GABAergic Interneurons in Amygdala & Cortex) - Bupivacaine: 'Fast In, Slow Out' kinetics
  • | - Prolongs QRS, PR, QTc intervals
  • Unopposed Excitatory NMDA Signaling - Re-entrant VT, Torsades, VF
  • | |
  • [ CNS EXCITATION ] 2. Inhibits Mitochondrial Energy Metabolism
  • Tinnitus, Metallic Taste, Lightheadedness, - Blocks Carnitine Palmitoyltransferase-1
  • Muscle Twitching, Generalized Tonic-Clonic Seizures - Uncouples Oxidative Phosphorylation
  • | |
  • Progressive Depressive Phase: 3. Depresses Myocardial Contractility
  • Coma, Apnea, Respiratory Arrest - Inhibits Intracellular Ca2+ Signaling
  • Severe Negative Inotropy & Asystole
  • The Bupivacaine Cardiotoxicity Mechanism: "Fast In, Slow Out"

While lidocaine and bupivacaine both bind to cardiac sodium channels ( N a V 1.5 Na_V1.5 N a V ​ 1.5 ), their dissociation kinetics differ radically:

Lidocaine ("Fast In, Fast Out"): Associates with the channel during Phase 0 systole and dissociates rapidly during Phase 4 diastole (recovery time constant about 0.15 seconds 0.15\text{ seconds} 0.15 seconds ). At physiological heart rates (60 to 80 bpm; diastolic interval ~0.6 seconds), lidocaine completely unbinds before the next action potential arrives.

Bupivacaine ("Fast In, Slow Out"): Associates rapidly during systole but dissociates about ten times more slowly during diastole (recovery time constant about 1.5 seconds 1.5\text{ seconds} 1.5 seconds ). Diastolic intervals are insufficient to allow channel clearance. Consequently, with each successive heartbeat, bupivacaine progressively accumulates in cardiac sodium channels, causing profound, cumulative conduction slowing, marked QRS widening, complete AV block, refractory re-entrant ventricular tachycardias, and electromechanical dissociation.

Cardiovascular Collapse to CNS Toxicity Ratio ( CC/CNS \text{CC/CNS} CC/CNS Ratio): The ratio of the dose required to produce irreversible cardiovascular collapse compared to that which provokes generalized seizures is 2.0 2.0 2.0 for bupivacaine , compared to 7.0 7.0 7.0 for lidocaine . Cardiotoxicity occurs almost simultaneously with CNS toxicity for bupivacaine.

Stereoisomer Safety Margin: Commercial bupivacaine is a 50:50 racemic mixture of R ( + ) R(+) R ( + ) and S ( − ) S(-) S ( − ) enantiomers. The R ( + ) R(+) R ( + ) -isomer binds the cardiac sodium channel pore with dramatically higher affinity and dissociates more slowly than the S ( − ) S(-) S ( − ) -isomer. Levobupivacaine (the pure S ( − ) S(-) S ( − ) -enantiomer of bupivacaine) and ropivacaine (a pure S ( − ) S(-) S ( − ) -propyl homolog) possess significantly wider therapeutic safety margins, exhibiting higher CC/CNS ratios and reduced cardiotoxic potential.

Physiological Factors Aggravating LAST

Acidosis and Hypercapnia: Acidemia decreases plasma protein binding to alpha-1-acid glycoprotein, doubling the concentration of free, biologically active local anaesthetic. Hypercapnia increases cerebral blood flow, accelerating drug delivery to the brain. Intracellular acidosis promotes intracellular ion trapping of the charged cation ( BH + \text{BH}^+ BH + ) inside cardiac myocytes, exacerbating channel blockade.

Hypoxemia and Hyperkalemia: Synergistically amplify conduction slowing and depress myocardial contractility.

6. Management of LAST: ASRA and Association of Anaesthetists Guidance

When Local Anaesthetic Systemic Toxicity is suspected, immediate, coordinated resuscitation must be initiated according to international guidance (the American Society of Regional Anesthesia and Pain Medicine 2020 checklist and the Association of Anaesthetists of Great Britain and Ireland LAST guideline). [ IMMEDIATE LAST RESUSCITATION ALGORITHM ]

  • |
  • +-----------------------------+-----------------------------+
  • | |
  • [ 1. STOP LA INJECTION ] [ 2. CALL FOR HELP & LAST RESCUE KIT ]
  • Immediate cessation of drug Summon Resuscitation Team
  • Secure Airway & 100% O2 Retrieve 20% Lipid Emulsion (Intralipid)
  • Hyperventilate mildly to prevent acidosis Alert ECMO / Perfusion Team Early
  • | |
  • +-----------------------------+-----------------------------+
  • |
  • v
  • [ 3. SUPPRESS SEIZURES & PREVENT HYPERCAPNIA ]
  • Benzodiazepines (Midazolam 1-2 mg IV) are first-line
  • Avoid propofol in hemodynamically unstable patients (potentiates cardiac depression)
  • Neuromuscular blocker (Succinylcholine) to halt muscular acidosis if seizures persist
  • |
  • v
  • [ 4. RESUSCITATION MODIFICATIONS (CRUCIAL ACLS CHANGES) ]
  • REDUCE Individual Epinephrine Boluses to <1 mcg/kg (e.g., 10-50 mcg boluses in adults)
  • (Large 1-mg doses impair resuscitation, worsen acidosis, and reduce lipid rescue efficacy)
  • AVOID Vasopressin (provokes adverse pulmonary and cardiac vasoconstriction)
  • AVOID Calcium Channel Blockers and Beta-Blockers (aggravate myocardial depression)

- AVOID Class I Antiarrhythmics (Lidocaine, Procainamide) -> Fatal Sodium Channel Toxicity!

  • |
  • v
  • [ 5. DEFINITIVE 20% LIPID EMULSION THERAPY (INTRALIPID) ]
  • BOLUS: 1.5 mL/kg IV over 1 minute (~100 mL in a 70-kg adult)
  • INFUSION: 0.25 mL/kg/min immediately (~18 mL/min; ~1000 mL/h)

- If cardiovascular instability persists:

  • * Repeat bolus of 1.5 mL/kg once or twice (every 3-5 minutes)
  • * Double the infusion rate to 0.5 mL/kg/min
  • Continue infusion for at least 15 minutes after hemodynamic stability is achieved
  • MAXIMUM Recommended Dose: 12 mL/kg within the first hour
  • Mechanisms of Lipid Rescue Therapy

Lipid Sink / Metabolic Shuttle: 20% lipid emulsion creates an expanded intravascular lipid compartment. Lipophilic local anaesthetic molecules are partitioned out of aqueous plasma into the lipid emulsion droplets, establishing a concentration gradient that draws toxic drug molecules away from myocardial and cerebral tissues.

Direct Metabolic Inotropy: High-dose fatty acid infusion overcomes local anaesthetic-induced inhibition of mitochondrial carnitine palmitoyltransferase-1 (CPT-1) , restoring substrate for beta-oxidation and ATP generation in the stunned myocardium.

Direct Membrane Ion Channel Effects: Free fatty acids promote opening of voltage-gated calcium channels, exerting an immediate positive inotropic effect and countering sodium channel block.

Cardiopulmonary Bypass / ECMO: If hemodynamic recovery does not occur following lipid emulsion and modified ACLS, venoarterial extracorporeal membrane oxygenation (VA-ECMO) provides bridge support while the liver and tissues metabolize the bound local anaesthetic.